Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Change in Receivables (2016 - 2025)

Historic Change in Receivables for Altimmune (ALT) over the last 16 years, with Q3 2025 value amounting to $524000.0.

  • Altimmune's Change in Receivables rose 1300000.0% to $524000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $417000.0, marking a year-over-year increase of 19287.31%. This contributed to the annual value of -$567000.0 for FY2024, which is 16044.78% down from last year.
  • Latest data reveals that Altimmune reported Change in Receivables of $524000.0 as of Q3 2025, which was up 1300000.0% from -$186000.0 recorded in Q2 2025.
  • In the past 5 years, Altimmune's Change in Receivables ranged from a high of $741000.0 in Q3 2023 and a low of -$3.1 million during Q3 2021
  • In the last 5 years, Altimmune's Change in Receivables had a median value of $3000.0 in 2022 and averaged -$198157.9.
  • As far as peak fluctuations go, Altimmune's Change in Receivables tumbled by 400000.0% in 2023, and later skyrocketed by 1300000.0% in 2025.
  • Over the past 5 years, Altimmune's Change in Receivables (Quarter) stood at -$1.1 million in 2021, then surged by 59.83% to -$460000.0 in 2022, then skyrocketed by 150.87% to $234000.0 in 2023, then plummeted by 50.43% to $116000.0 in 2024, then surged by 351.72% to $524000.0 in 2025.
  • Its Change in Receivables was $524000.0 in Q3 2025, compared to -$186000.0 in Q2 2025 and -$37000.0 in Q1 2025.